ABSTRACT

Purpose: We evaluated the risk of contralateral breast cancer (CBC) and ipsilateral breast tumor recurrence (IBTR) and investigated the predictive factors for CBC and IBTR in breast cancer patients with BRCA mutations and non-carriers at high-risk of hereditary breast and ovarian cancer (HBOC).

Methods: We analyzed prospectively collected clinical data of patients with unilateral breast cancer who were at high-risk for HBOC and were tested for the BRCA mutation between 2003 and 2013.

Results: The cohort comprised 540 patients with 45 BRCA1 carriers, 50 BRCA2 carriers, and 445 non-carriers. The median follow-up was 84.5 months. Overall, 61 patients (11.3%) developed CBC (24.4% for BRCA1 carriers, 20% for BRCA2 carriers, and 9% for non-carriers). The 10-year cumulative risk for CBC was 23.8% for BRCA1 carriers, 19.1% for BRCA2 carriers, and 9.8% for non-carriers (p = 0.174). Among the 277 patients who underwent breast-conserving surgery, 29 (10.5%) developed IBTR (9.1% for BRCA1 carriers, 16.7% for BRCA2 carriers, and 10.2% for non-carriers). The 10-year cumulative risk for IBTR for BRCA1 carriers, BRCA2 carriers, and non-carriers was 8.7%, 14.1%, and 20%, respectively (p = 0.577). BRCA1 (hazard ratio [HR], 2.94; 95% confidence interval [CI], 1.20–7.20; p = 0.019) and BRCA2 (HR, 2.88; 95% CI, 1.13–7.35; p = 0.027) mutations and negative estrogen receptor status (HR, 4.02; 95% CI, 1.60–10.08; p = 0.003) were the significant predictive factors for CBC, while tumor size ≥ 2 cm was predictive of IBTR (HR, 6.11; 95% CI, 2.03–18.33; p = 0.001).

Conclusion: While BRCA1/2 mutation carriers had a higher risk of developing CBC compared to non-carriers at high-risk of HBOC, the risk of IBTR was similarly high across breast cancer patients irrespective of the BRCA mutation. Further preventive strategies to reduce CBC and IBTR for all patients at high-risk of HBOC should be investigated.
Keywords: Breast neoplasms; Genes, BRCA1; Genes, BRCA2; Hereditary breast and ovarian cancer syndrome; Risk factors

INTRODUCTION

Approximately 5%–10% of breast cancer patients are carriers of at least one breast cancer susceptibility gene, including BRCA1, BRCA2, TP53, PTEN, LKB1, and MSH2/MLH1 [1], and most hereditary breast cancers are derived from BRCA1 and BRCA2 mutations [2]. Women with a germline mutation in either the BRCA1 or BRCA2 gene have a high-risk of developing breast cancer over their lifetime [3-5]. One meta-analysis showed that women with BRCA1 and BRCA2 mutations had 57% and 49% risks of developing breast cancer by the age of 70 years, respectively [4]. Compared to patients with sporadic breast cancer, women with BRCA1- and BRCA2-associated breast cancer are reported to have 4.5- and 3.4-fold increased risks of contralateral breast cancer (CBC), respectively [6]. In addition, several studies have shown a higher risk of ipsilateral breast tumor recurrence (IBTR) in patients with BRCA-associated breast cancer treated with breast-conserving surgery (BCS) than in sporadic controls who received BCS [7-10].

The Korean Hereditary Breast Cancer study, a large prospective nationwide study to estimate the prevalence of BRCA1/2 mutations and ovarian cancer among a high-risk group of patients with hereditary breast cancer and their families, has reported average cumulative risks of breast cancer of 72.1% and 66.3% among BRCA1 and BRCA2 mutation carriers, respectively, by the age of 70 years [5,11]; furthermore, the risks of CBC at 5 years after primary breast cancer were 16.2% and 17.3%, respectively.

The purpose of this study was to assess the risks of CBC and IBTR and to determine the predictive factors for CBC and IBTR among invasive breast cancer patients at high-risk of hereditary breast and ovarian cancer (HBOC) according to the germline mutations of the BRCA1/2 genes.

METHODS

We analyzed prospectively collected cohort data of 772 patients at high-risk of HBOC who underwent genetic testing for BRCA1/2 mutations between 2003 and 2013 at Seoul National University Bundang Hospital. The indication for BRCA testing was as follows: 1) having at least one third-degree relative with breast or ovarian cancer, 2) young breast cancer patients (age at diagnosis ≤ 40 years), 3) breast cancer patients with multiple primary cancers, 4) male breast cancer patients, and 5) breast cancer patients from a family with known BRCA mutations. Among those who received genetic testing for BRCA1/2 mutations, study subjects included patients who underwent curative surgery for invasive breast cancer. Patients with synchronous bilateral breast cancer were excluded because the purpose of this study included an evaluation of the risk of CBC. We also excluded patients who underwent total mastectomy when analyzing the risk of IBTR (Figure 1).

Data on age at diagnosis, tumor size, nodal status, histologic grade of tumor, estrogen receptor (ER) status, human epidermal growth factor receptor-2 (HER2) expression, operation methods, chemotherapy, radiotherapy, bilateral oophorectomy, familial tree for
breast cancer, and information on CBC and IBTR were collected from medical records. CBC was defined as a newly diagnosed tumor in the contralateral breast after treatment of the first breast cancer. IBTR was defined as all events that occurred in the ipsilateral remnant breast tissue after BCS. We did not distinguish between true recurrence and new primary cancer, but any ipsilateral event within 6 months after surgery was considered a local failure and excluded from IBTR.

Written informed consent was obtained from all patients, and this study was approved by the Institutional Review Board (IRB) of Seoul National University Bundang Hospital (IRB No. B-1701/377-102).

**Statistical analysis**

The date of the last follow-up was defined as the date of last contact or death. The Kaplan-Meier product-limit method was used to calculate the cumulative risks of developing CBC or IBTR after the first breast cancer, while the log-rank test was used to compare the cumulative risks between groups. We also compared the risk of developing CBC and IBTR according to tumor characteristics (ER, HER2, and nodal status), the number of first-
degree relatives with breast cancer, and the type of treatment received including surgery, chemotherapy, radiotherapy, hormone therapy, and oophorectomy. In these analyses, oophorectomy was treated as a time-dependent covariate. Cox proportional hazards regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). IBM SPSS Statistics version 22 (IBM Corp, Armonk, NY, USA) was used for cumulative risks, and R version 3.3.2 (http://www.R-project.org/) was used for the HRs. A $p$-value < 0.05 was considered statistically significant.

RESULTS

Patient characteristics

Among 124 patients with the BRCA mutation, 29 were excluded because they did not undergo surgery (n = 3), had bilateral lesions (n = 8), had stage IV cancer at the time of diagnosis (n = 11), and had non-invasive breast cancer (n = 7). Meanwhile, among 598 non-carriers with a high-risk of HBOC, 153 patients were excluded because they did not undergo surgery (n = 8), had bilateral lesions (n = 39), had stage IV cancer at the time of diagnosis (n = 11), had non-invasive breast cancer (n = 68), and had missing information (n = 27). Finally, a total of 540 patients were included in this study. Of these, 45 patients had the BRCA1 mutation, 50 patients had the BRCA2 mutation, and 445 were identified as BRCA-negative or with variants of unknown significance. The median follow-up period was 7.04 years (range, 0.16–30.9 years).

The patient characteristics are presented in Table 1. The proportion of younger patients (i.e., those aged younger than 50 years) was higher in BRCA1 mutation carriers than in BRCA2 mutation carriers and non-carriers; only 6.7% of BRCA1 mutation carriers were aged over 50 years, whereas 26.0% of BRCA2 carriers and 17.9% of non-carriers were aged over 50 years. Lymph node metastasis was more prevalent in BRCA2 mutation carriers than in BRCA1 mutation carriers and non-carriers. ER-negative tumors were also more prevalent in BRCA1 mutation carriers, but HER2-positive tumors were more prevalent in non-carriers. There were 9 male breast cancer patients, all of whom were non-carriers.

CBC

Sixty-one patients (11.3%) developed CBC (11/45 [24.4%] patients with the BRCA1 mutation, 10/50 [20%] patients with the BRCA2 mutation, and 40/445 [9%] without BRCA1/2 mutations). The median time from surgical treatment of the first breast cancer to CBC was 5.3 years (range, 1.4–25.7 years) for BRCA1 mutation carriers, 7.0 years (range, 0.8–25.9 years) for BRCA2 mutation carriers, and 6.6 years (range, 0.16–24.1 years) for non-carriers. The 10-year cumulative risk for CBC after the first breast cancer was 23.8% for BRCA1 mutation carriers, 19.1% for BRCA2 mutation carriers, and 9.8% for non-carriers with high risks of HBOC ($p = 0.174$, Figure 2).

Univariate and multivariate analyses were performed to assess the predictive factors for CBC (Table 2). In the univariate analysis, BRCA1 mutation, negative ER status, and having a first-degree relative with breast cancer were statistically significant predictive factors. Meanwhile, in the multivariate model that included BRCA mutation, age at diagnosis, ER status, hormone therapy, and having a first-degree relative with breast cancer, the Cox proportional hazards regression model showed the BRCA1 (HR, 2.94; 95% CI, 1.20–7.20; $p = 0.019$) and BRCA2 (HR, 2.88; 95% CI, 1.13–7.35; $p = 0.027$) mutations and negative ER status (HR, 4.02; 95% CI, 1.60–10.08; $p = 0.003$) were the independent predictors of CBC.
## Table 1. Characteristics of study subjects

| Variable                        | BRCA1 (n = 45) | BRCA2 (n = 50) | Non-carrier (n = 445) | p-value |
|---------------------------------|----------------|----------------|-----------------------|---------|
| **Age at diagnosis (yr)**       |                |                |                       | 0.047   |
| ≤ 30                            | 7 (15.6)       | 6 (12.0)       | 46 (10.3)             |         |
| 31–40                           | 28 (62.2)      | 22 (44.0)      | 218 (48.0)            |         |
| 41–50                           | 7 (15.6)       | 9 (18.0)       | 101 (22.7)            |         |
| 51–60                           | 3 (6.7)        | 7 (14.0)       | 42 (9.4)              |         |
| > 60                            | 0 (0.0)        | 6 (12.0)       | 38 (8.5)              |         |
| **Tumor size**                  |                |                |                       | 0.152   |
| < 2 cm                          | 17 (43.6)      | 16 (32.0)      | 221 (50.7)            |         |
| ≥ 2 cm                          | 22 (56.4)      | 28 (56.0)      | 215 (49.3)            |         |
| Unknown                         | 6              | 6              | 9                     |         |
| **Nodal status**                |                |                |                       | 0.001   |
| Negative                        | 26 (66.7)      | 14 (31.1)      | 248 (56.8)            |         |
| Positive                        | 13 (33.3)      | 31 (68.9)      | 189 (43.2)            |         |
| Unknown                         | 6              | 5              | 8                     |         |
| **Histologic grade**            |                |                |                       | < 0.001 |
| I                               | 1 (3.0)        | 1 (2.5)        | 62 (16.1)             |         |
| II                              | 5 (15.2)       | 27 (67.5)      | 156 (40.6)            |         |
| III                             | 27 (81.8)      | 12 (30.0)      | 166 (43.2)            |         |
| Unknown                         | 12             | 10             | 61                    |         |
| **ER status**                   |                |                |                       | < 0.001 |
| Positive                        | 11 (25.0)      | 35 (71.4)      | 292 (66.1)            |         |
| Negative                        | 33 (75.0)      | 14 (28.6)      | 150 (33.9)            |         |
| Unknown                         | 1              | 1              | 3                     |         |
| **HER2 status**                 |                |                |                       | 0.003   |
| Positive                        | 3 (8.3)        | 1 (2.5)        | 92 (22.0)             |         |
| Negative                        | 33 (91.7)      | 39 (97.5)      | 326 (78.0)            |         |
| Unknown                         | 9              | 10             | 27                    |         |
| **Operation method**            |                |                |                       | 0.001   |
| BCS                             | 33 (73.3)      | 18 (36.0)      | 226 (50.8)            |         |
| Mastectomy                      | 12 (26.7)      | 32 (64.0)      | 219 (49.2)            |         |
| **Chemotherapy**                |                |                |                       | 0.002   |
| No                              | 4 (9.1)        | 7 (14.0)       | 128 (28.8)            |         |
| Yes                             | 40 (90.9)      | 43 (86.0)      | 316 (71.2)            |         |
| Unknown                         | 1              | 0              | 1                     |         |
| **Hormone therapy**             |                |                |                       | < 0.001 |
| No                              | 32 (78.0)      | 13 (26.0)      | 144 (32.7)            |         |
| Yes                             | 9 (22.0)       | 37 (74.0)      | 297 (67.3)            |         |
| Unknown                         | 4              | 0              | 4                     |         |
| **Radiation therapy**           |                |                |                       | 0.012   |
| No                              | 6 (14.0)       | 21 (42.0)      | 144 (32.5)            |         |
| Yes                             | 37 (86.0)      | 29 (58.0)      | 293 (67.5)            |         |
| Unknown                         | 2              | 0              | 2                     |         |
| **Oophorectomy**                |                |                |                       | < 0.001 |
| No                              | 22 (48.9)      | 29 (58.0)      | 437 (98.2)            |         |
| Yes                             | 23 (51.1)      | 21 (42.0)      | 8 (1.8)               |         |
| **Family history of breast cancer** |            |                |                       | 0.004   |
| No                              | 18 (40.0)      | 13 (26.0)      | 254 (57.1)            |         |
| Yes                             | 27 (60.0)      | 37 (74.0)      | 191 (42.9)            |         |
| **Family history of ovarian cancer** |            |                |                       | 0.480   |
| No                              | 35 (77.8)      | 47 (94.0)      | 428 (96.2)            |         |
| Yes                             | 10 (22.2)      | 3 (6.0)        | 17 (3.8)              |         |
| **First-degree relative with breast cancer** |   |                |                       | < 0.001 |
| 0                               | 25 (55.6)      | 20 (40.0)      | 337 (75.7)            |         |
| 1                               | 18 (40.0)      | 24 (48.0)      | 100 (22.5)            |         |
| 2+                              | 2 (4.4)        | 6 (12.0)       | 8 (1.8)               |         |

Values are presented as number (%). ER = estrogen receptor; HER2 = human epidermal growth factor receptor-2; BCS = breast-conserving surgery.
Of the 277 patients who underwent BCS, 29 were diagnosed with IBTR (3/33 [9.1%] of 33 BRCA1 mutation carriers, 3/18 [16.7%] of BRCA2 mutation carriers, and 23/226 [10.2%] of non-carriers). The median time from BCS to IBTR was 4.9 years (range, 1.4–23.9 years) for BRCA1 mutation carriers, 5.9 years (range, 0.8–11.4 years) for BRCA2 mutation carriers, and 6.3 years (range, 0.4–23.9 years) for non-carriers. The 10-year cumulative risk for IBTR was 8.7% for BRCA1 mutation carriers, 14.1% for BRCA2 mutation carriers, and 20% for high-risk non-carriers ($p = 0.577$, Figure 3).

In multivariate analyses to assess the predictive factors for IBTR (Table 3), only tumor size $\geq$ 2 cm was a statistically significant predictive factor for IBTR (HR, 6.11; 95% CI, 2.03–18.33; $p = 0.001$), while the other factors did not increase the risk of IBTR.
DISCUSSION

Women with a history of breast cancer are known to have an increased risk for CBC. According to the Surveillance, Epidemiology, and End Results database, breast cancer survivors have an approximately 1.5- to 2-fold increased risk for subsequent CBC compared to the risk of developing breast cancer in the general population [12]. Furthermore, compared to patients with sporadic breast cancer, women with BRCA1- and BRCA2-associated breast cancer have 4.5- and 3.4-fold increased risks of CBC, respectively [6]. The risk of CBC in patients with BRCA-associated breast cancer is 1.5%–3.1% annually, with 10-year estimates of 25%–38% for mutation carriers from high-risk families compared with a 3%–7% rate for

### Table 2. Relative risks of contralateral breast cancer associated with selected factors (all)

| Variable                           | Univariate | Multivariate |
|------------------------------------|------------|--------------|
|                                    | HR (95% CI) | p-value     | HR (95% CI) | p-value     |
| Mutation type                      |            |              |            |              |
| Non-carrier                        | 1.0        | 1.0          | 1.0        | 1.0          |
| BRCA1                              | 1.98 (0.98–4.01) | 0.059 | 2.94 (1.20–7.20) | 0.019 |
| BRCA2                              | 1.40 (0.67–2.90) | 0.367 | 2.88 (1.13–7.35) | 0.027 |
| Age at diagnosis                   |            |              |            |              |
| ≤ 50                               | 1.0        | 1.0          | 1.0        | 1.0          |
| > 50                               | 0.63 (0.33–1.20) | 0.157 | 0.64 (0.80–3.46) | 0.770 |
| Tumor size                         |            |              |            |              |
| < 2 cm                             | 1.0        |              | 1.0        |              |
| ≥ 2 cm                             | 0.90 (0.51–1.60) | 0.724 |              |              |
| Nodal status                       |            |              |            |              |
| Negative                           | 1.0        |              | 1.0        |              |
| Positive                           | 1.13 (0.65–1.98) | 0.657 |              |              |
| Histologic grade                   |            |              |            |              |
| I                                  | 1.0        |              | 1.0        |              |
| II                                 | 2.06 (0.60–7.08) | 0.251 |              |              |
| III                                | 2.05 (0.60–6.95) | 0.251 |              |              |
| ER status                          |            |              |            |              |
| Positive                           | 1.0        |              | 1.0        |              |
| Negative                           | 4.06 (2.17–7.58) | < 0.001 | 4.02 (1.60–10.08) | 0.003 |
| HER2 status                        |            |              |            |              |
| Positive                           | 1.0        |              | 1.0        |              |
| Negative                           | 0.76 (0.36–1.60) | 0.470 |              |              |
| Operation method                   |            |              |            |              |
| BCS                                | 1.0        |              | 1.0        |              |
| Mastectomy                         | 0.91 (0.53–1.55) | 0.718 |              |              |
| Chemotherapy                       |            |              |            |              |
| No                                 | 1.0        |              | 1.0        |              |
| Yes                                | 0.84 (0.49–1.43) | 0.515 |              |              |
| Hormone therapy                    |            |              |            |              |
| No                                 | 1.0        |              | 1.0        |              |
| Yes                                | 0.61 (0.36–1.03) | 0.066 | 1.14 (0.44–2.92) | 0.791 |
| Radiation therapy                  |            |              |            |              |
| No                                 | 1.0        |              | 1.0        |              |
| Yes                                | 1.35 (0.77–2.37) | 0.301 |              |              |
| Oophorectomy                       |            |              |            |              |
| No                                 | 1.0        |              | 1.0        |              |
| Yes                                | 1.24 (0.44–3.47) | 0.682 |              |              |
| First-degree relative with breast cancer |          |              |            |              |
| 0                                  | 1.0        |              | 1.0        |              |
| 1                                  | 0.56 (0.28–1.06) | 0.084 | 0.56 (0.25–1.26) | 0.363 |
| 2+                                 | 3.32 (1.12–9.78) | 0.012 | 1.29 (0.36–4.58) | 0.699 |

ER = estrogen receptor; HER2 = human epidermal growth factor receptor-2; BCS = breast-conserving surgery; HR = hazard ratio; CI = confidence interval.
women without mutations [6-8]. Metcalfe et al. [13] reported that the 15-year actuarial risk of CBC was 36.1% for BRCA1 mutation carriers and 28.5% for BRCA2 mutation carriers. In their study, the 10-year risk of CBC was 23.8% for women with a BRCA1 mutation and 18.7% for those with a BRCA2 mutation [13], which is consistent with our results.

Meanwhile, the 10-year risk of CBC in women with sporadic breast cancer was reported to be about 5%, which was significantly lower than that in BRCA mutation carriers [14,15]. In the current study, the 10-year risk of CBC in non-carriers at high-risk of HBOC was 9.8%, which is approximately 2 times higher than in those with sporadic breast cancer. A report from the Women’s Environment, Cancer and Radiation Epidemiology study supports our results and demonstrates 10-year cumulative risks of CBC for non-carriers with no family history, second-degree family history only, a first-degree family history, and a history of bilateral breast cancer in a first-degree relative of 4.6%, 5.9%, 8.6%, and 15.6%, respectively [15].

### Table 3. Relative risks of ipsilateral breast tumor recurrence associated with selected factors (all)

| Variable                                | Univariate HR (95% CI) | p-value | Multivariate HR (95% CI) | p-value |
|------------------------------------------|------------------------|---------|--------------------------|---------|
| Mutation type                            |                        |         |                          |         |
| Non-carrier                              | 1.0                    |         |                          |         |
| BRCA1                                    | 0.80 (0.23–2.81)       | 0.731   |                          |         |
| BRCA2                                    | 1.90 (0.57–6.35)       | 0.297   |                          |         |
| Age at diagnosis                         |                        |         |                          |         |
| ≤ 50                                     | 1.0                    |         |                          |         |
| > 50                                     | 0.70 (0.48–1.02)       | 0.060   | 1.16 (0.39–3.44)         | 0.785   |
| Tumor size                               |                        |         |                          |         |
| < 2 cm                                   | 1.0                    |         |                          |         |
| ≥ 2 cm                                   | 2.31 (1.24–4.31)       | 0.009   | 6.11 (2.03–18.33)        | 0.001   |
| Nodal status                             |                        |         |                          |         |
| Negative                                 | 1.0                    |         |                          |         |
| Positive                                 | 1.52 (0.72–3.19)       | 0.269   |                          |         |
| Histologic grade                         |                        |         |                          |         |
| I                                        | 1.0                    |         |                          |         |
| II                                       | 0.63 (0.23–1.74)       | 0.371   |                          |         |
| III                                      | 0.57 (0.21–1.57)       | 0.275   |                          |         |
| ER status                                |                        |         |                          |         |
| Positive                                 | 1.0                    |         |                          |         |
| Negative                                 | 1.93 (0.88–4.25)       | 0.101   | 1.54 (0.41–5.74)         | 0.522   |
| HER2 status                              |                        |         |                          |         |
| Positive                                 | 1.0                    |         |                          |         |
| Negative                                 | 0.76 (0.26–2.25)       | 0.640   |                          |         |
| Chemotherapy                             |                        |         |                          |         |
| No                                       | 1.0                    |         |                          |         |
| Yes                                      | 1.14 (0.51–2.58)       | 0.750   |                          |         |
| Hormone therapy                          |                        |         |                          |         |
| No                                       | 1.0                    |         |                          |         |
| Yes                                      | 0.54 (0.26–1.12)       | 0.096   | 1.29 (0.34–4.93)         | 0.711   |
| Radiation therapy                        |                        |         |                          |         |
| No                                       | 1.0                    |         |                          |         |
| Yes                                      | 0.76 (0.10–5.60)       | 0.785   |                          |         |
| Oophorectomy                             |                        |         |                          |         |
| No                                       | 1.0                    |         |                          |         |
| Yes                                      | 1.81 (0.63–5.26)       | 0.273   |                          |         |
| First-degree relative with breast cancer |                        |         |                          |         |
| 0                                        | 1.0                    |         |                          |         |
| 1                                        | 0.98 (0.40–2.14)       | 0.960   |                          |         |
| 2+                                       | 1.49 (0.01–11.12)      | 0.790   |                          |         |

ER = estrogen receptor; HER2 = human epidermal growth factor receptor-2; HR = hazard ratio; CI = confidence interval.
Several factors are reported to influence the risk of CBC in BRCA mutation carriers with breast cancer. Younger age at the time of first breast cancer diagnosis is reported to be associated with a higher risk of CBC in patients with a BRCA mutation [6,13]. Malone et al. [6] reported that the relative risk (RR) of CBC for BRCA mutation carriers increased as the age of first diagnosis increased. Metcalfe et al. [13] reported that women aged younger than 50 years are at significantly higher risk of developing CBC in 15 years than those aged older than 50 years. In the current study, however, we could not analyze the risk factors of CBC according to the BRCA mutation status because the number of patients who developed CBC in each group was too small; therefore, we analyzed all patients who were at high-risk of HOBC irrespective of the BRCA mutation. Thus, in the current study, age < 50 years was not significantly associated with an increased risk of developing CBC, although the risk of CBC tended to be higher in younger patients than in older patients.

Previous studies have found a 1.3- to 1.8-fold higher risk of CBC in BRCA1 mutation carriers than in BRCA2 mutation carriers [6,16,17]. We showed that patients with BRCA1/2 mutations have a significantly higher risk of developing CBC than do high-risk non-carriers, though we failed to show any significant difference in the risk of developing CBC between BRCA1 and BRCA2 carriers. This is probably due to the limited sample size and inadequate length of follow-up. In Metcalfe’s study [13], the ER status of primary cancer was not associated with the risk of CBC. However, in general, patients with ER-positive tumors are considered to be at decreased risk for CBC [18]. In our study, negative ER status of the primary tumor was found to be a significant predictive factor for increased risk of CBC, probably because we analyzed the risk factors of CBC by combining both BRCA mutation carriers and high-risk non-mutation carriers.

BCS combined with radiotherapy is a standard treatment for early-stage breast cancer and yields a survival rate equivalent to that in mastectomy in women with sporadic breast cancer [19,20]. Among breast cancer patients treated with BCS, BRCA mutation carriers have a reportedly higher risk of ipsilateral in-breast events, including IBTR and the development of a second primary tumor, compared to sporadic controls [7-10]. In a multi-institutional study by Pierce et al. [8], the 10-year rate of IBTR was twice as high among BRCA1/2 mutation carriers treated with BCS than among sporadic controls who received BCS. Another multi-institutional study demonstrated that compared with BRCA mutation carriers treated with mastectomy, carriers who underwent BCS had an elevated risk of local failure in the ipsilateral breast, most occurrences of which appeared to be second primary cancers rather than failure to control the primary tumor [21]. Metcalfe et al. [22] also reported a 10-year risk of IBTR of 11% for women with a BRCA1 mutation and 17% for women with a BRCA2 mutation, which closely corresponds to our results. However, we found no significant difference in the development of IBTR between BRCA1/2 mutation carriers and high-risk non-carriers, which was likely because we compared BRCA mutation carriers with high-risk non-carriers and not with sporadic breast cancer patients. In the study by Kirova et al. [23], there was also no difference in the risk of IBTR between BRCA mutation carriers and non-carriers with a family history of breast and/or ovarian cancer.

The chief treatment goal in patients with breast cancer is to minimize the risk of death from primary breast cancer. For women with BRCA-associated breast cancer, however, minimizing the incidence of and mortality due to subsequent cancers, such as metachronous CBC and ovarian cancer, is equally as important as treating the primary breast cancer. While intensified screening may help identify subsequent cancers at an early and favorable stage, it cannot prevent the development of such cancers. Therefore, preventive strategies, such as contralateral prophylactic mastectomy (CPM), prophylactic oophorectomy (PO), or chemoprevention
with tamoxifen may be considered in patients with BRCA mutations to reduce their risk for developing subsequent cancer. CPM has been reported to reduce the risk of CBC by at least 90% [24], and a meta-analysis has shown that PO is associated with a decreased risk of CBC in patients with BRCA1/2-associated breast cancer (RR, 0.52; 95% CI, 0.37–0.74) [25]. Tamoxifen also decreased the incidence of CBC [16,26], and its use was associated with a 50% reduction in the risk of CBC in BRCA mutation carriers independent of the protective effect of PO [26].

PO may also help reduce the risk of IBTR in patients with BRCA-associated breast cancer treated with BCS. Pierce et al. [8] have shown that the rates of IBTR were twice as high among BRCA1/2 mutation carriers who did not undergo PO than among sporadic controls, though the rates were similar between mutation carriers who underwent PO and sporadic controls. Metcalfe et al. [22] also reported that PO was associated with a significant reduction in the risk of IBTR in patients with BRCA mutations, particularly for BRCA1 mutation carriers. In the study by Pierce et al. [8], the use of tamoxifen was associated with a 63% reduction in IBTR among patients who did not undergo PO. Moreover, although data on the survival of BRCA-associated breast cancer patients who opt for subsequent CPM are inconsistent [27], PO appears to be associated with improved breast and ovarian cancer-specific mortality as well as improved all-cause mortality among BRCA1/2 mutation carriers [28].

Although we assessed a prospectively collected cohort data of patients with BRCA mutations at high-risk of HBOC, a study limitation is its single-center, retrospective design. The small number of patients in each subgroup resulted in weak statistical power and a wide CI. Furthermore, all of the patients assessed were Korean and represented an ethnically homogenous Far East Asian population; however, the characteristics of Korean patients with BRCA mutation-associated breast cancer are not different from those of Western patients [29]. Another potential limitation is the insufficient follow-up period; follow-up should span more than 10 years since the risk of developing CBC or IBTR in BRCA mutation carriers continues to increase over time, as do the differences in the risk levels among sporadic patients [7,8]. In the current study, we were unable to observe a reduction in CBC and IBTR associated with oophorectomy, probably because the preventive effect of oophorectomy among BRCA1/2 mutation carriers is only evident 15 years after the procedure [30]. In this study, the number of younger patients was higher among BRCA1 mutation carriers than among BRCA2 mutation carriers and non-carriers. However, the effect of age was not considered when calculating the cumulative risk, which could be a weakness of this study.

In conclusion, the results of this study show that both BRCA1/2 mutation carriers and non-carriers at high-risk of HBOC are at high-risk of developing CBC and IBTR. Our results emphasize the importance of careful history taking, including a detailed family history, to determine whether the patient is at high-risk of HBOC. Counseling for preventive measures, regardless of BRCA1/2 mutation status, should be considered in such patients. Further preventive strategies to reduce the risk of CBC and IBTR in BRCA mutation carriers and non-carriers with a high-risk of HBOC should be investigated.

REFERENCES

1. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318-24.

PUBMED | CROSSREF
2. Robson ME, Boyd J, Borgen PI, Cody HS 3rd. Hereditary breast cancer. Curr Probl Surg 2001;38:387-480.

3. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.

4. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33.

5. Han SA, Park SK, Ahn SH, Son BH, Lee MH, Choi DH, et al. The breast and ovarian cancer risks in Korea due to inherited mutations in BRCA1 and BRCA2: a preliminary report. J Breast Cancer 2009;12:92-9.

6. Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol 2010;28:2404-10.

7. Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 2002;359:1471-7.

8. Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006;24:2437-43.

9. Turner BC, Harrold E, Matloff E, Smith T, Gumbs AA, Beinfield M, et al. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol 1999;17:3017-24.

10. Garcia-Etienne CA, Barile M, Gentilini OD, Botteri E, Rotmensz N, Sagona A, et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol 2009;16:3380-7.

11. Kang E, Kim SW. The Korean hereditary breast cancer study: review and future perspectives. J Breast Cancer 2013;16:245-53.

12. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys 2003;56:1038-45.

13. Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2011;104:1384-92.

14. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 2007;43:867-76.

15. Reiner AS, John EM, Brooks JD, Lynch CF, Bernstein L, Mellemkjær L, et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the women’s environmental cancer and radiation epidemiology study. J Clin Oncol 2013;31:433-9.

16. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:2328-35.

17. Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009;27:5887-92.

18. Lizarraja IM, Sugg SL, Weigel RJ, Scott-Conner CE. Review of risk factors for the development of contralateral breast cancer. Am J Surg 2013;206:704-8.

19. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233-41.
20. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:1227-32. PUBMED | CROSSREF

21. Pierce LJ, Phillips KA, Griffith KA, Buys S, Gaffney DK, Moran MS, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat 2010;121:389-98. PUBMED | CROSSREF

22. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, et al. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2011;127:287-96. PUBMED | CROSSREF

23. Kirova YM, Savignoni A, Sigal-Zafrani B, de La Rochefordiere A, Salmon RJ, This P, et al. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat 2010;120:119-26. PUBMED | CROSSREF

24. Schrag D, Kuntz KM, Garber JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 2000;283:617-24. PUBMED | CROSSREF

25. Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat 2014;144:443-55. PUBMED | CROSSREF

26. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000;356:1876-81. PUBMED | CROSSREF

27. Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev 2018;4:CD002748. PUBMED

28. Eleje GU, Eke AC, Ezebiolu IU, Ikechebelu JJ, Ugwu EO, Okonkwo OO. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database Syst Rev 2018;8:CD012464. PUBMED

29. Yu JH, Lee JW, Son BH, Kim SW, Park SK, Lee MH, et al. Characteristics of BRCA1/2 mutation-positive breast cancers in Korea: a comparison study based on multicenter data and the Korean Breast Cancer Registry. J Breast Cancer 2014;17:129-35. PUBMED | CROSSREF

30. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005;23:7491-6. PUBMED | CROSSREF